Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin versus placebo in type 2 diabetes
IRCT20191126045505N1Phase 3Completed
- Sponsor
- North Khorasan University of Medical Sciences
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in type 2 diabetes mellitus (T2DM) comparing Empagliflozin recipient with Placebo recipient (2 arms). Primary endpoints: Glycemic indexes, Liver function and 5 more. Started Jun 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20191126045505N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191126045505N1.